Rapamycin targets STAT3 and impacts c-Myc to suppress tumor growth

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Rapamycin is a known mTOR inhibitor used clinically as an immunosuppressant.
• Emerging evidence suggests rapamycin's efficacy in anti-cancer, anti-aging, and neurodegenerative disease applications.
• Identifying novel targets of rapamycin is crucial for understanding its mechanisms and expanding its therapeutic uses.

Purpose of the Study:

• To identify novel functional protein targets of rapamycin using chemical proteomics.
• To investigate the direct interaction between rapamycin and STAT3 (Signal Transducer and Activator of Transcription 3).
• To evaluate the impact of rapamycin on STAT3 and c-Myc expression and their downstream effects in cancer models.

Main Methods:

• Chemical proteomics strategy to identify rapamycin-binding proteins.
• Multi-dimensional proteomics analysis.
• Cell culture experiments to assess gene expression changes.
• In vivo xenograft mouse model for hepatocellular carcinoma.

Main Results:

• STAT3 was identified as a direct functional protein target of rapamycin.
• Rapamycin treatment significantly inhibited c-Myc-regulated gene expression in cell culture.
• Rapamycin suppressed tumor growth in a hepatocellular carcinoma xenograft model.
• Decreased expression of STAT3 and c-Myc was observed in tumors treated with rapamycin.

Conclusions:

• Rapamycin directly targets STAT3, reducing its transcriptional activity.
• This study provides a novel mechanism for rapamycin's anti-cancer effects.
• The findings support the development of STAT3 inhibitors for cancer therapy, with rapamycin as a potential lead compound.